SCHEMBL21551399

SCHEMBL21551399

CC(=O)NCC1CCN(Cc2cc(Oc3ccc(N4CC[C@H](NC(=O)O)[C@H](F)C4)nc3)cc(-c3cc(Cl)cc(Cl)c3)c2)CC1

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ FURIN P09958 11/20 0.59
▸ CHRM2 P08172 3/20 0.42
▸ CHRM1 P11229 3/20 0.42
▸ CHRM4 P08173 3/20 0.41
▸ FAAH O00519 1/20 0.40
▸ BCHE P06276 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ KCNH2 Q12809 1/20 0.39
▸ CACNA1I Q9P0X4 1/20 0.39
▸ CHRM5 P08912 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ MCHR1 Q99705 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21551401 1.00 FURIN (0.59) FURINCHRM2CHRM1CHRM4FAAH
SCHEMBL21551397 1.00 FURIN (0.59) FURINCHRM2CHRM1CHRM4FAAH
SCHEMBL21564572 0.92 FURIN (0.54) FURINCHRM2CHRM1CHRM4CHRM5
SCHEMBL29890932 0.92 FURIN (0.54) FURINCHRM2CHRM1CHRM4CHRM5
SCHEMBL29199010 0.92 FURIN (0.54) FURINCHRM2CHRM1CHRM4CHRM5
SCHEMBL29199011 0.92 FURIN (0.54) FURINCHRM2CHRM1CHRM4CHRM5
SCHEMBL26077365 0.91 FURIN (0.60) FURINCHRM2CHRM1CHRM4FAAH
SCHEMBL24872438 0.90 FURIN (0.59) FURINCHRM2CHRM1CHRM4KCNH2
SCHEMBL21551017 0.90 FURIN (0.59) FURINCHRM2CHRM1CHRM4KCNH2
SCHEMBL21551019 0.90 FURIN (0.59) FURINCHRM2CHRM1CHRM4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 — — EP disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 — — US disclosed
US-20220315556-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-10-06 — — US disclosed
EP-3790871-A1 FURIN INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2021-03-17 — — EP disclosed
WO-2019215341-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315556-A1 FURIN INHIBITORS FURIN, TGFB1, PCSK7 FURIN 1/4885CHRM2 3813/4885CHRM1 3955/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 FURIN 1/4885CHRM2 3813/4885CHRM1 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback